A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

4170

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Breast Cancer

Interventions

DRUG: Giredestrant
DRUG: Physician's Choice of Endocrine Therapy
DRUG: LHRH Agonist

Sponsor

Hoffmann-La Roche